Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?

References

• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male ageing study. J Clin Endocrinol Metab 2002;87:589–98
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. The Aging Male 2007;10:139–53
   PubMed Web of Science ®Google Scholar
• Maggio M, Ceda GP, Lauretani F, et al. Gonadal status and physical performance in older men. Aging Male 2011;14:42–7
   PubMed Web of Science ®Google Scholar
• Haring R, Ittermann T, Völzke H, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania. Aging Male 2010;13:247–57
   PubMed Web of Science ®Google Scholar
• Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249–54
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829–37
   PubMed Web of Science ®Google Scholar
• ESC guidelines: acute and chronic heart failure. Available from: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/acute-chronic-heart-failure.aspx
   Google Scholar
• Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A boil Sci Med Sci 2001;52:88–96
   Google Scholar
• Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526–34
   PubMed Web of Science ®Google Scholar
• Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393–7
   PubMed Web of Science ®Google Scholar
• Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179–83
   PubMed Web of Science ®Google Scholar
• Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels the dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000;85:1834–40
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Filippatos G, Ponikowska B, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 2009;15:442–50
   PubMed Web of Science ®Google Scholar
• Grzesło A, Jankowska EA, Witkowski T, et al. Clinical significance and prognostic value of anemia in heart failure patients. Kardiol Pol 2007;65:184–91
   Google Scholar
• Jankowska EA, Drohomirecka A, Ponikowska B, et al. Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 2010;12:966–73
   PubMed Web of Science ®Google Scholar
• Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:76–80
   PubMedGoogle Scholar
• Rezvani MR, Saadatjou SA, Sorouri S, Hassanpour Fard M. Comparison of serum free testosterone, luteinizing hormone and follicle stimulating hormone levels in diabetics and non-diabetics men- a case-control study. J Res Health Sci 2012;12:98–100
   PubMedGoogle Scholar
• Baba S, Murai M, Jitsukawa S, et al. Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men. J Urol 1978;119:375–80
   Google Scholar
• Erbler HC. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man. Arch. Pharmacol 1974;285:403–6
   Google Scholar
• Menard RH. Loriaux DL, Bartter FC, Gillette JR. The effect of the administration of spironolactone on the concentration of plasma testosterone, estradiol and cortisol in male dogs. Steroids 1978;31:771–82
   Google Scholar
• Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem 1985;23:191–4
   PubMedGoogle Scholar
• Lin H, Wang SW, Tsai SC, et al. Inhibitory effect of digoxin on testosterone secretion through mechanisms involving decreases of cyclic AMP production and cytochrome P450sc activity in rat testicular interstitial cells. Br J Pharmacol 1998;125:1635–40
   Google Scholar
• Neri A, Zukerman Z, Aygen M, et al. The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction. J Sex Marital Ther 1987;13:58–63
   PubMed Web of Science ®Google Scholar
• Kley HK, Muller A, Peerenboom H, Kruskemper HL. Digoxin does not alter plasma steroid levels in health men. Clin Pharmacol Ther 1982;32:12–17
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247–54
   PubMed Web of Science ®Google Scholar
• Pastor-Pérez FJ, Manzano-Fernández S, Garrido Bravo IP, et al. Anabolic status and functional impairment in men with mild chronic heart failure. Am J Cardiol 2011; 108:862–6
   PubMedGoogle Scholar
• Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288–96
   PubMed Web of Science ®Google Scholar
• Pu HF, Wang SW, Tseng CI, et al. Mechanisms of digoxin and digitoxin on the production of corticosterone in zona fasciculate-reticularis cells of ovariectomized rats. J Cell Biochem 2006;97:303–13
   Google Scholar
• Bicíková M, Hill M, Hampl R, Stárka L. Inhibition of rat renal and testicular 11 beta-hydroxysteroid dehydrogenase by some antihypertensive drugs, diuretics, and epitestosterone. Horm Metab Res 1997;29:465–8
   Google Scholar
• Pitt B, Zannad F, Willem J. Remme, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–17
   PubMed Web of Science ®Google Scholar
• Cuculi F, Suter A, Erne P. Spironolactone-induced gynecomastia. CMAJ 2007;176:620–3
   Google Scholar
• Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag 2011;7:353–63
   PubMedGoogle Scholar
• Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431–9
   PubMed Web of Science ®Google Scholar
• Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759–64
   PubMed Web of Science ®Google Scholar
• Benedict C, Johnstone DE, Kirlin PC, et al. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart-failure – a substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation 1990;82:1724–9
   Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure – activation of the neurohumoral axis. Ann Intern Med 1985;103:1–6
   PubMed Web of Science ®Google Scholar
• Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311–15
   PubMed Web of Science ®Google Scholar
• Gao H-B, Ge R-S, Vijaya Lakshmi, et al. Hormonal regulation of oxidative and reductive activities of 11β-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 1997;138: 156–61
   PubMed Web of Science ®Google Scholar
• Monder C, Hardy MP, Blanchard RJ, Blanchard DC. Comparative aspects of 11 beta-hydroxysteroid dehydrogenase. Testicular 11 beta-hydroxysteroid dehydrogenase: development of a model for the mediation of Leydig cell function by corticosteroids. Steroids 1994;59:69–73
   PubMed Web of Science ®Google Scholar
• Monder C, Sakai RR, Miroff Y, et al. Reciprocal changes in plasma corticosterone and testosterone in stressed male rats maintained in a visible burrow system: evidence for a mediating role of testicular 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1994;134:1193–8
   PubMed Web of Science ®Google Scholar
• Monder C, Miroff Y, Marandici A, Hardy MP. 11β-hydroxysteroid dehydrogenase alleviates glucocorticoid-mediated inhibition of steroidogenesis in rat Leydig cells. Endocrinology 1994;134:1199–204
   PubMed Web of Science ®Google Scholar
• Metra M, Zacà V, Parati G, et al; Heart Failure Study Group of the Italian Society of Cardiology. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 2011;12:76–84
   PubMed Web of Science ®Google Scholar
• Chim CL, Donna MM. Non-cardiac comorbidities in chronic heart failure. Heart 2007;93:665–71
   Google Scholar
• McGann PE. Comorbidity in heart failure in the elderly. Clin Geriatr Med 2000;16:631–48
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Forti G, Maggi M. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? Int J Androl 2009;32:431–41
   PubMedGoogle Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011;34:1669–75
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011;26:184–90
   Google Scholar
• Torkler S, Wallaschofski H, Baumeister SE, et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male 2011;14:176–82
   PubMed Web of Science ®Google Scholar
• Laghi F. Low testosterone in chronic obstructive pulmonary disease does it really matter? Am. J Respir Crit Care Med 2005;172:1069-70
   PubMed Web of Science ®Google Scholar
• Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J 2009;34:975–96
   PubMed Web of Science ®Google Scholar
• Colangelo LA, Chiu B, Kopp P, et al. Serum IGF-I and C-reactive protein in healthy black and white young men: The CARDIA Male Hormone Study. Growth Horm IGF Res 2009;19: 420–5
   Google Scholar
• Efstratiadis G, Tsiaousis G, Athyros VG, et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006;57:303–11
   PubMed Web of Science ®Google Scholar